Flatiron Health launches new collaboration to advance cancer care with the latest evidence-based treatment and clinical research entry at the point of care

Flatiron Health announces new collaboration with Penn Medicine’s Abramson Cancer Center to advance the evolution of cancer care through Flatiron Assist™ enabling the latest evidence-based oncology medicine and clinical research recruitment at the point of care. 

Oncology real-world evidence technology innovator Flatiron Health has announced the launch of a new collaboration with Penn Medicine Abramson Cancer Center (ACC), a market-leading cancer care provider. The new agreement will see the Flatiron Assist clinical decision support platform enable ACC clinicians real-time access to evolving evidence-based treatment guidelines, site-preferred pathways, and clinical research opportunities at the point of care. This access can elevate cancer care, fostering high levels of guideline-concordant treatment, whilst improving health equity and patient experiences, and reducing unnecessary spending.  

Flatiron Assist is an oncology-specific electronic health record (EHR)-integrated clinical decision support platform that delivers the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for the 26 most common cancers, as well as site-preferred treatment pathways and relevant clinical trial opportunities for patients at the point of care. It enables real-time access to the most up-to-date evidence-based treatment guidelines, promoting advanced cancer care insights for oncology clinicians.  

Flatiron report that cancer centers using Flatiron Assist typically see 80% clinician adoption, which has driven positive outcomes for centers to date, yielding results such as: 

• 88% care concordance with NCCN guidelines; 
• 84% selection of site-preferred regimens; and 
• 44% reduction in unique regimens. 

Speaking exclusively to The Evidence Base, Julia Morton, Serving VP and GM of Flatiron HC, said:

“The partnership with Penn’s ACC is pivotal in advancing the evolution of cancer care. Their invaluable feedback and profound impact on our tool, Flatiron Assist, not only enhance its usability for physicians but also guide us toward a future where patient-centric innovation drives progress in the realms of technology and cancer care. After demonstrating success within their thoracic group, Flatiron is excited to continue supporting Penn ACC as they author custom pathways across various cancer types, integrated within Flatiron Assist in their EHR.” 

As well as raising awareness of clinical research opportunities and opening clinical trials at the point of care, a focus of the collaboration will be to enable ACC clinicians to determine and develop ACC-preferred pathways across sub-specialties. The two organizations will also work together to optimize the usability and functionality of Flatiron Assist, and will track usage patterns and tie the results to financial impacts for the health system. 

“We are excited to support our oncology clinicians in providing evidence-based treatment while improving clinical and administrative efficiencies,” said Lawrence Shulman, MD, a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania and the Associate Director of Special Projects at ACC. “As cancer care options increase in complexity, this tool will help provide high-quality, guideline-concordant care, maximizing benefits for our patients.”